Clinical Trials for Myelodysplastic Syndromes

201011766

Tissue Acquisition for Analysis of Genetic Progression Factors in Hematologic Diseases Phase N/A Principal Investigator Westervelt, Peter Disease Site Hodgkin’s Lymphoma; Leukemia, other; Lymphoid Leukemia; Multiple Myeloma; Myeloid and Monocytic Leukemia; Non-Hodgkin’s Lymphoma; Other Hematopoietic

201708159

A Phase 3 Randomized Double-Blind Placebo-Controlled Study Investigating the Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia in Patients with Lower Risk Myelodysplastic Syndrome (MDS) with Low Red Blood Cell (RBC) Transfusion Burden…

201905082

A Phase Ib Study of AZD6738 for Patients with Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Progressing on Front-Line Therapy Phase I (Cancer Control) Principal Investigator Jacoby, Meagan Disease Site Myeloid and Monocytic Leukemia; Other Hematopoietic…

201906041

A Phase 1b Study of SEL120 in Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Phase I Principal Investigator Abboud, Camille Disease Site Myeloid and Monocytic Leukemia; Other Hematopoietic Learn more about this study…

201910101

A Multi-Center Phase 2 Study of Combined Modality Treatment with Ruxolitinib, Decitabine, and Donor Lymphocyte Infusion for Post-Transplant Relapse of AML or MDS Phase II Principal Investigator Schroeder, Mark Disease Site Myeloid and Monocytic Leukemia;…

201911201

Identification of AML/MDS drug sensitization by in vivo chemotherapy administration Phase N/A Principal Investigator Welch, John Disease Site Myeloid and Monocytic Leukemia; Other Hematopoietic Learn more about this study at: clinicaltrials.gov

202007148

ENHANCE: A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination with Azacitidine versus Azacitidine Plus Placebo in Treatment-naïve Patients with Higher Risk Myelodysplastic Syndrome Phase III (Cancer Control) Principal Investigator Abboud, Camille Disease Site Other…

202011122

A Phase 2 Trial Evaluating the Efficacy of Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (allo-HCT) Phase II Principal Investigator Christopher, Matthew Disease Site Myeloid and…